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Hepatitis C virus (HCV) is a major cause of severe liver disease, and one major contributing factor is
thought to involve a dysfunction of virus-specific T-cells. T-cell receptor (TCR) gene therapy with
HCV-specific TCRs would increase the number of effector T-cells to promote virus clearance. We
therefore took advantage of HLA-A2 transgenic mice to generate multiple TCR candidates against
HCV using DNA vaccination followed by generation of stable T-cell–BW (T-BW) tumour hybrid
cells. Using this approach, large numbers of non-structural protein 3 (NS3)-specific functional T-
BW hybrids can be generated efficiently. These predominantly target the genetically stable HCV
genotype 1 NS31073–1081 CTL epitope, frequently associated with clearance of HCV in humans.
These T-BW hybrid clones recognized the NS31073 peptide with a high avidity. The hybridoma
effectively recognized virus variants and targeted cells with low HLA-A2 expression, which has not
been reported previously. Importantly, high-avidity murine TCRs effectively redirected human non-
HCV-specific T-lymphocytes to recognize human hepatoma cells with HCV RNA replication driven
bya subgenomicHCVreplicon. Takentogether, TCRcandidateswith a range of functional avidities,
which can be used to study immune recognition of HCV-positive targets, have beengenerated. This
has implications for TCR-related immunotherapy against HCV.
INTRODUCTION
It is estimated that 180 million individuals are infected
with hepatitis C virus (HCV) worldwide today, of which
130 million are chronic carriers at risk of developing liver
cirrhosis and liver cancer. Being a small, enveloped RNA
virus, HCV is one of the most persistent viruses in humans,
and spontaneous resolution of HCV infection only occurs
in a minority of the infected (Alter, 2006). Considering the
steady increase of reported incidence in Europe (Rantala &
van de Laar, 2008), a reduction of HCV prevalence is not
anticipated in the near future.
Analyses of individuals who have resolved their HCV
infection have indicated that a successful immunity
requires effector T-cells. CD4
+ and CD8
+ lymphocyte
activation early in the infection is associated strongly with
eradication of HCV infection (Cucchiarini et al., 2000;
Diepolder et al., 1996; Lechner et al., 2000; Pape et al., 1999;
Schulze zur Wiesch et al., 2005), and an early development of
polyfunctional T-cells further predicts a spontaneous resolu-
tion of HCV infection (Badr et al., 2008). However, failure
to sustain virus-specific CD8
+ lymphocytes is frequently
observed in chronically infected patients (Lechner et al.,
2000). T-cells from these patients are associated with features
such as functional exhaustion (Kantzanou et al., 2003;
Radziewicz et al., 2007), developmental arrest (Cox et al., A supplementary figure is available with the online version of this paper.
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et al., 2003) and impairment in proliferative capacity and
effector function (Wedemeyer et al., 2002), which are
thought to be a consequence of continued antigen stimu-
lation and/or a viral factor related to antigen-presenting cell
(Bain et al., 2001; Goutagny et al., 2003; Nattermann et al.,
2006; Ulsenheimer et al., 2005; Wertheimer et al., 2007).
A successful immune response in people infected with HCV
is characterized by strong and persistent CTL responses. One
well-defined CTL epitope is the HCV non-structural protein
3(N S3 ) 1073–1081peptide(NS31073),andresponsesagainstthis
epitope are often found in spontaneous resolution of HCV
infection, which are well-maintained after spontaneous
recovery of HCV (Wertheimer et al., 2003). Several vaccines
that target induction of NS3-specific T-cell immunity are
currently being tested in clinical trials (Thompson &
McHutchison, 2009). Recently, a novel strategy for engin-
eering new effector T-cells against NS31073 via gene transfer
ofaT-cellreceptor(TCR)invitrowasdescribed(Zhangetal.,
2010). Given the observation that the NS31073 epitope can be
associated with cross-reactivity with an influenza A virus
(IAV) neuraminidase (NA) epitope, and that cross-reactive
CD8
+ T-cells have been found in fulminant acute hepatitis
patients (Urbani et al., 2005), access to T-cells that differ in
functional avidity would be desirable for comparison.
To date, only one NS31073-specific human TCR (Zhang et al.,
2010) has been identified and no murine alternatives are
available. Murine TCRs present several advantages over human
TCRs in gene modification of human T-cells, including an
enhanced and more sustained level of surface expression and
improved anti-tumour activity (Kieback & Uckert, 2010).
Moreover, a recent murine TCR gene-therapy trial that targeted
tumour antigens demonstrated a therapeutic effect in cancer
patients, although some immune responses to murine TCR
variable regions were found in a subset of patients (Davis et al.,
2010). Given these facts, we therefore chose to explore the
HLA-A2 transgenic (HHD) mouse model to establish more
HCV TCR gene candidates. Here a large number of functional
NS3-specific T-cell–BW (T-BW) hybrid clones were obtained
by fusing the BW5147 cell line and activated splenocytes cells
from HHD mice immunized with an electroporation-enhanced
HCV NS3 DNA vaccine. The results indicate that the T-BW
hybrid clones are highly specific to the NS31073 of HCV
genotype 1a and 1b variants. Differences were found regarding
their functional avidity and affinity to the NS31073/HLA
complex pentamer, as well as their ability to respond to
human hepatoma cells harbouring HCV subgenomic RNA.
RESULTS
Generation of HLA-A2-restricted mouse T-BW
hybrid clones specific to HCV NS3
We used CD8
+ T-cells from HHD (HLA-A2 transgenic)
mice (Pascolo et al., 1997) immunized with the electropora-
tion-delivered codon-optimized HCV DNA vaccine coNS3/
4A-pVAX1, and performed cell fusion with BW TCR
neg cells.
Single-cell cloning was carried out under hypoxanthine–
aminopterin–thymidine (HAT) selection. T-BW hybridized
clones that survived selection were screened for the surface
expression of CD3 and positive clones were tested against
human T2 cells (a lymphoblastic cell line) loaded with
the HLA-A2-restricted NS31073 (CINGVCWTV) or NS31406
(KLVALGVNAV) peptide. Analysis of interleukin-2 (IL-2)
and gamma interferon (IFN-c) release in the supernatant
demonstrated that nine of them recognized the NS31073-
loadedT2cellsandnonerecognizedthatloadedwithNS31406
(Fig. 1a). The reactivity was confirmed by retesting on T2
cells as well as on HHD splenocytes (Fig. 1a–d). TCR/CD3
surface expression for the respective clones was 51% (I8H4),
81% (I8A4), 79% (I4G7), 85% (I4F8), 95% (I2B11), 95%
(I4E9), 84% (I6B3),52% (I7B7)and 89% (I4F9) at the time
of the assays.
During the screening process, the hybrid clones were
regularly subcloned and checked for CD3 expression to
ensure that they maintained a stable CD3 expression and IL-
2 activity (Supplementary Fig. S1, available in JGV Online).
Although the clone I8A4 demonstrated repetitively low
response against NS31073, the percentage of live CD3-
expressing cells and the cell-surface CD3 expression of this
clone were similar to the others at the time of testing. None
of the clones showed CD8 surface expression (data not
shown), which is analogous to previous reported BW-
derived T-cell clones (Rock et al., 1990); thus, the cytokine
release detected here is independent of the CD8 cofactor.
TCR gene usage of NS31073-specific T-BW cell
hybrid clones
Examination of the TCR usage of these T-BW hybrid
clones was done in order to assess the TCR responsible for
recognizing NS31073. RNA was isolated from each of these
clones and at least five TCR a and b gene products were
sequenced. Sequence analysis showed that six of the nine
clones were sister clones (Fig. 2a); AV9 and BV2 gene usage
and an identical third complementarity-determining region
(CDR3) sequence were found in I4F8, I2B11, I4E9, I6B3,
I7B7 and I4F9. The AV9 gene was also used by I4G7, which
has a unique CDR3 coding sequence using AJ27. The AV16
and AV2 genes were used by I8H4 and I8A4, respectively,
and have their own CDR3 with different AJ genes. The TCR
b genes were likewise determined for all clones. Three
clones utilized VB13 with various subfamilies BV13-1
(I8H4), BV13-2 (I8A4), and BV13-3 and BV13-1 were
found in I4G7 and they all used different BD and BJ genes.
The I4F8 and its sister clones all used the BV2 gene and
shared identical CDR3 nucleotide sequences.
Here, the CDR3a and CDR3b loops were between 10–13
and 11–14 aa residues, respectively. They exhibit a type II
pattern bias (Turner et al., 2006) that is characterized by
the preference of the motifs ‘KLTFG’ (CDR3a loops) and
‘GG’ (CDR3b loops). A commonly found motif in the BJ
segments here was ‘FGPGTR’, which is reported only in
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genes (IMGT Repertoire IG and TR database; http://www.
imgt.org/IMGTrepertoire/). Interestingly, the same three
motifs also exist in a recently reported human TCR that is
specific to the NS31073 peptide (Zhang et al., 2010). This
result suggests that highly conserved CDR3 motifs are shared
by the murine and human TCRs that are specific to the
NS31073 peptide.
Affinity to NS31073/HLA-A2 pentamer
Since the T-BW hybrid clones lack the CD8 coreceptor,
which might be required for the stabilization of the TCR-
peptide/HLA complex (Roszkowski et al., 2003), we next
asked whether any of these clones could bind the NS31073/
HLA-A2 pentamer. Following incubation with an R-
phycoerythrin (R-PE)-labelled NS31073/HLA-A2 pentamer,
the fluorescence intensity of the staining was quantified
by flow cytometry. Compared with the negative-control
pentamer HBVcore18–27-HLA-A2, it was found that I8H4,
one of the high-avidity clones, had an increased fluo-
rescence in NS31073/HLA-A2 pentamer staining (Fig. 2b).
Comparison of the functional avidity
We next asked whether the functional avidity in these T-
cell hybrid clones might differ. The clones were regularly
subcloned and checked by FACS and were tested when the
TCR/CD3 expression was at least 50% at the time of the
experiment. They were tested with T2 target cells pulsed
with diluted amounts of NS31073 peptide and the results
showed that, while I8A4 required at least 400 ng peptide
ml
21 to obtain a half-maximum response of IL-2 release,
about 10 ng peptide ml
21 was sufficient for stimulating
I8H4, I4G7 and I4F8 for a half-maximum response of IL-2
release (Fig. 3). The TCR/CD3 surface expression was 51%
(I8H4), 82% (I8A4), 88% (I4G7) and 93% (I4F8) at the
time of this experiment. The experiment was performed
three times with similar results. Based on these data, I8A4
is ranked as a low-avidity T-cell clone, while I8H4, I4G7
and I4F8 resemble moderate/high-avidity T-cells described
previously (McKee et al., 2005).
Cross-genotype reactivity
We next asked whether these clones cross-reacted with
other viral peptides, in particular the naturally occurring
genotypes of HCV NS31073 and the IAV NA, Flu-NA231,t o
which cross-reactivity to HCV NS31073 of genotype 1b
strain has been described (Wedemeyer et al., 2001). Shown
in Fig. 4, we found that these T-cell clones were activated
only when cultured with the genotype 1a and 1b peptide
of the HCV NS31073. None of the other HCV genotype
peptide variants tested was sufficiently stimulatory to
induce substantial IL-2 production, although all variants
displayed significant binding affinity to the HLA-A2
molecule (Fytili et al., 2008). No IL-2 production was
found against the Flu-NA peptide (Fig. 4) or other viral
peptides, including the HCV non-structural protein 5
(NS5) peptide NS52221 and NS51992 SPDADLIEANL and
VLTDFKTWL, and human cytomegalovirus (HCMV)
pp65495 NLVPMVATV (data not shown). The TCR/CD3
surface expression was 97% (I8H4), 70% (I8A4), 99%
(I4G7) and 95% (I4F8) at the time of this experiment. The
Fig. 1. (a) Screening summary for the BW-fused HHD T-BW
hybrid clones. Cytokine production against HHD or HLA-A2 target
cells loaded with NS31073. (b) IL-2 secretion upon stimulation with
HHD splenocytes loaded with NS31073. (c) IL-2 and (d) IFN-c
secretion upon stimulation with T2 cells loaded with NS31073 (&)
or NS31406 (h). Depicted fold induction is given as the ratio of
cytokine concentration in co-cultures containing peptide-loaded
target (10 mg indicated peptide ml
”1) over the unloaded control
(0 mg indicated peptide ml
”1). Mean values of duplicate co-
cultures from one experiment are shown. Amount of cytokine
released (pg ml
”1) is shown on the top of each bar. *Not detected.
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for genotype 1 of HCV NS3.
Relevance of each amino acid position of NS31073
peptide for hybridoma reactivity
Since amino acid positions 2, 7, 9 and positions 3, 4, 5 of
NS31703 are key positions in HLA binding and interaction
with human TCR (So ¨derholm et al., 2006), respectively, we
next tested whether they have relevance for the four murine
T-BW hybrid clones, 18H4, 18A4, 14G7 and 14F8. Alanine-
substituted peptide analogues of NS31073 loaded ono T2
cells in descending concentrations were tested against these
T-cell clones. As shown in Fig. 5, alanine substitutions at
position 3, 4, 5 and 7 completely abolished the IL-2 release
in all four T-cell clones, which is in line with that observed
for human T-cells. Complete or partial IL-2 release in
response to alanine substitutions at position 1, 2, 6, 8 and 9
was, however, obtained in high-avidity clones, and was also
observed at reduced peptide concentrations. This was
unfortunately not observed for I8A4 (low avidity), which
responded only to alanine substitution at position 1 and
none of the other substitutions. The TCR/CD3 surface
expression was 51% (I8H4), 82% (I8A4), 88% (I4G7) and
93% (I4F8) at the time of this experiment.
Recognition of target cells with low HLA-A2
expression
T2 cells are a lymphoblastic cell line commonly used as
antigen-presenting cells for loading exogenous peptide
and, due to the constitutive HLA-A.2 expression and TAP
(transporter associated with antigen processing) deficiency,
the density of these target molecules is often saturated.
We next asked whether our T-cell hybrid clones recognize
target cells that have low HLA-A2 expression. The
hepatoblastoma Huh-6 and C1R-A2 cell lines were chosen
for this experiment. Cell-surface expression of HLA-A2
assessed by staining with an anti-HLA-A2 mAb (Fig. 6a)
after NS31073 peptide stabilization showed that both cell
lines have lower HLA-A2 expression than T2 cells. Huh-6
cells showed the lowest HLA-A2 expression, as only a
Fig. 2. (a) Summary of TCR gene usage and CDR3 coding sequences of the nine IL-2
+IFN-c
+ T-BW hybrid clones. (b) Affinity
to the NS31073/HLA-A2 pentamer. Indicated T-cell clones were stained with R-PE-labelled NS31073/HLA-A2 pentamer (black
line unfilled) or control R-PE-labelled HBV core18–27 pentamer (grey filled) and labelled with FITC-labelled anti-mouse CD3
antibody and analysed by FACS. Histograms of fluorescence intensity of pentamer staining were gated on the live CD3
+
population.
Fig. 3. Functional avidity of T-BW hybrid clones (I8H4, $; I8A4,
#; I4G7, &; I4F8, h) tested against T2 cells loaded with
descending concentration of NS31073. Comparative results were
obtained in three separate experiments.
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with the negative-control C1R-null cell line (Fig. 6b). We
then assessed IL-2 production in the T-cell clones co-
cultured with these target cells. Shown in Fig. 6(c), NS31073
peptide-loaded C1R-A2 cells could stimulate significant IL-
2 production in all four T-cell lines, at a similar magnitude
to that observed for the T2 target cells. Significant IL-2
release against the peptide-loaded Huh-6 cells was, however,
Fig. 4. Cross-reactivity against other viral
peptides that share similarity with the
NS31073 peptide sequence encoded by the
DNA vaccine (genotype 1a). Overnight IL-2
production in T-BW hybrid clones against T2
cells loaded with the indicated viral peptide
(10 mg peptide ml
”1) was measured for each
T-cell clone and is shown as a percentage
of IL-2 production by genotype 1a of the
NS31073 peptide. Amino acids that differ from
the genotype 1a are indicated in bold. Mean
values and SD of triplicate co-cultures are
shown. Flu, Flu-NA231; gt, genotype.
Fig. 5. Responses to the alanine-substituted peptide analogues of NS31073. Overnight IL-2 production in T-BW hybrid clones
(I8H4, $; I8A4, #; I4G7, &; I4F8, h) co-cultured with T2 cells loaded with descending concentrations of the alanine-
substituted peptides of NS31073 (substituted from positions 1 to 9). Mean values of duplicate co-cultures are shown.
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clone (Fig. 6d). TCR/CD3 surface expression was 90%
(I8H4), 80% (I8A4), 89% (I4G7) and 90% (I4F8) at the
time of this experiment.
Reactivity against HCV RNA replicon hepatoma
cells
We next analysed the ability of the T-cell hybrids to
recognize the Huh-7/Lunet HCV replicon cells that
harbour the subgenomic HCV replicon. Huh-7/Lunet
hepatoma replicon cells maintain constant levels of HCV
replication over several years and represent an excellent
model of persistent HCV infection (Bartenschlager &
Sparacio, 2007). As Huh-7 cells lack HLA-A2 expression,
they are stably transduced with lentiviral vectors expressing
HLA-A2 and a selectable marker encoding the blasticidin-
resistance gene, and transfected with the HCV genotype
1b Con1-ET subgenomic replicon and a selection marker
conferring the neomycin-resistance gene by using an
approach described previously (Ahle ´n et al., 2007). As
shown in Fig. 7(b), antigen-specific IL-2 production by
the T-cell clones was detected after co-culture at different
ratios with peptide (NS31073 genotype 1a)-loaded HCV
replicon cells harbouring both the Con1-ET replicon and
HLA-A2 (R-neo/A2) or control cells expressing only the
HLA-A2 (A2). In these cultures both IL-2 and IFN-c were
detected, particularly from the high-avidity I8H4, I4F8 and
I4G7 T-cell clones, and this indicates that the lentiviral-
transferred HLA expression is functional. The TCR/CD3
surface expression was 90% (I8H4), 80% (I8A4), 89%
(I4G7) and 90% (I4F8) at the time of the experiment. In
the same experiment, we investigated whether these T-cell
clones recognized the replicon cells directly without
addition of exogenous peptide. Shown in Fig. 7(a), IL-2
production was detected in the co-culture of the I8H4 and
HLA-A2-positive HCV replicon cells (R-neo/A2), and this
IL-2 production was dependent on the ratio of the added
cells. No IFN-c was detected (data not shown). Stimulation
with HCV replicon cells without HLA-A2 expression or
cells with HLA-A2 expression only did not stimulated
any IL-2 release from the I8H4. This result concurs with
previous results that I8H4 is the only clone with affinity
to the NS31073/HLA-A2 pentamer (Fig. 2) and has an
increased response to genotype 1b sequence (Fig. 4) and
the Huh-6 target cells (Fig. 6).
Transfer of TCR genes into naı ¨ve non-HCV
specific human T-cells
Although BW hybridomas are a good model to assess
TCR functions, they have a limited clinical application
in humans. To know whether murine TCRs identified
here are functional to redirect non-HCV-specific human
Fig. 6. HLA-A2 expression in the B-lympho-
cyte C1R-A2 cell line (a, filled grey) and the
hepatoblastoma Huh-6 cell line (b, filled grey)
loaded with NS31073 peptide compared with
that of the C1R-null cells (solid line no fill) and
T2 cells (dotted line). (c, d) IL-2 secretion in
T-BW hybrid clones following co-culture with
(c) C1R-A2 cells (&) or C1R-null (h) cells or
(d) Huh-6 cells loaded with 10 mg NS31073
peptide ml
”1. Mean values and SD of duplicate
co-cultures are shown. Similar results were
obtained in two separate experiments.
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+ cells, peripheral blood lym-
phocytes (PBLs) from healthy human donors were thus
transduced with retroviral vectors packaged with genes
encoding I8H4 TCR and the I4F8 TCR, which reacted
strongly against the NS31073 peptide in previous experi-
ments. Surface expression of the respective TCRs following
retroviral transduction was detected following transduc-
tion in 10–20% CD3
+ T-cells and not noticeably in mock,
untransduced PBL controls (,0.15%) stained with the
mouse Vb antibodies. Transduced T-cells, here defined as
mouseVb
+humanCD8
+-expressing cells, were found to
produce significant amounts of IFN-c when stimulated with
NS31073 1a or 1b peptide-loaded T2 cells (Fig. 8a). Tumour
necrosis factor alpha (TNF-a) was found frequently in this
IFN-c
+ population and a ‘triple’-positive population (IL-
2
+TNF-a
+ IFN-c
+) was clearly demonstrated (Fig. 8b).
The CTL function was studied on luciferase-producing
bioluminescent Huh-7/Lunet HCV replicon cells (HLA-
A2
+ Luc-ubi-neo Con1
+) that had been co-incubated with
transduced T-cells using a charge-coupled device (CCD)
camera. Images were taken at 20 h after co-incubation and
analysed by Living Image software (version 4.2; Caliper Life
Sciences). The analysis showed an efficient elimination of
bioluminescent HCV replicon cells that have been co-
incubated with I4F8 and I8H4 TCR-transduced T-cells
(Fig.8c,d),anda significant increaseofhepatocellularaspar-
tate transaminase was also detected in these co-culture
supernatants when compared with those co-incubated
with mock-transduced T-cells (Fig. 8e). In conclusion, our
data indicate that murine TCRs identified by the current
approach can provide antigen specificity to naı ¨ve non-HCV-
specific T-cells to generate new effector T-cells that are
polyfunctional and can eliminate HCV RNA-replicating
hepatoma cells.
DISCUSSION
In this study, we describe identification of new HCV-
specific T-cell clones in the HLA-A2 transgenic mouse
Fig. 7. Cytokine release against the Huh-7/
Lunet-derived HCV replicon cells. (a) IL-2
concentration in T-BW hybrid clone I8H4,
I8A4, I4F8 or I4G7 co-cultured with the Lunet-
HlaA2-neoET (R-neo/A2) replicon cells that
harbour both the HCV Con1-ET subgenomic
replicon and HLA-A2, or co-cultured with
control cell lines Lunet-blr/neo ET (R-neo) or
Lunet-HlaA2 neo (A2) that harbour only the
HCV replicon or HLA-A2, respectively. (b) IL-2
and IFN-c concentration in the T-BW hybrid
clones co-cultured with Lunet-HlaA2-neoET
(R-neo/A2) HCV replicon cells, or the control
Lunet-HlaA2 neo (A2) cells that express HLA-
A2 but no HCV replicon, that were loaded with
NS31073 peptide (genotype 1a, 10 mgm l
”1).
Co-cultures consisted of 110
5 of indicated
Lunet cells and T-BW cells in the ratio 1:1 or
1:5. Mean values and SD of duplicate co-
cultures are shown.
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ation and stable immortalization of these T-cell clones
via somatic-cell hybridization with the BW5147 cell line.
These T-cell clones recognize the NS31073 epitope, which is
one of the most important CTL epitopes in hepatitis C
often associated with spontaneous resolution of HCV
infection (Wertheimer et al., 2003). As shown here, they
are highly specific to NS31073 and cross-recognition is
restricted within genotype 1a and 1b virus variants and not
to other related viral sequences tested. This is interesting
because genotypes 1a and 1b viruses are found in up
to 70% of infected patients in the USA and Europe.
Moreover, these clones differ from each other with regard
to their functional avidity and affinity. This resembles the
discrepancy in T-cell avidity observed in humans between
donors who have recovered from HCV infection and
chronically infected patients (Neveu et al., 2008). In this
regard, the high-avidity clones I8H4, I4G7 and I4F8
generated in this study have similar EM50 (effective molarity)
values (approx. 10 ng ml
21)t ot h o s ef o u n di nC D 8
+ T-cells
in individuals who have recovered from HCV infection,
whilecloneI8A4,whichhasa 10–100-fold-higherEM50value
(400 ng ml
21), resembles the T-cells found in chronically
infected patients (Neveu et al., 2008). Furthermore, there has
been an elegant study by Kasprowicz et al.( 2 0 0 8 )i nw h i c hi t
was demonstrated that NS31073-specific T-cells that are CD8-
independent might represent cells of higher functions, i.e.
require substantially less viral peptide as well as fewer cells to
achieve the effector function. This might be of relevance for
the mouse TCRs reported here, as they were raised in the
absence of human CD8 and are capable of recognizing the
target cells in a CD8-independent manner.
To our knowledge, this is the first study that has examined
the TCR repertoire that is induced by an HCV vaccine. The
TCR repertoire induced by natural infection of HCV has
so far described the b chain (Miles et al., 2011), but it is
interesting to find that our murine TCRs not only share
similar CDR3 lengthsto those found there,but also thesame
sequence motifs found in a human NS31073 TCR (Zhang
et al., 2010). Given the conserved nature of these motifs, it
is likely that they play a key role in the interface between
TCR and antigen contacts, tickling the T-cell to respond.
Moreover, our report is the first to demonstrate that HCV-
specific T-cell hybridomas of different functional avidities
towards a human HCV CTL target can be generated rapidly
by DNA vaccination of HHD mice. Studies of HCV antigen
presentation often require substantial amounts of HCV-
specific lymphocytes/primary human T-cells (Accapezzato
et al., 2005; Barth et al., 2005, 2008; Lapenta et al., 2006)
but, because of the short lifespan and the requirement of
repetitive antigen stimulation with primary T-cell lines, an
alternative approach to obtaining large amounts of HCV-
specific T-cells would be of interest. The T-cell hybrid
Fig. 8. Multiple effector functions in the TCR-expressing naı ¨ve
HCV-non-specific CD8 T-cells co-cultured with peptide-loaded T2
cells or the endogenous viral peptide in HCV Con1 genotype
1b replicon cells. (a) Intracellular IFN-c staining on mouse
(mu)Vb
+humanCD8
+ lymphocytes in transduced T-cells co-cul-
tured overnight with peptide (NS31073 1a or 1b)-loaded T2 cells or
controls, and (b) intracellular TNF-a and IL-2 staining in the IFN-c
+
population in (a). (c) Bioluminescence of HCV replicon-encoded
luciferase activity in Lunet-HlaA2-Luc-ubi-neo Con1 replicon cells
that have been co-incubated with human T-cells transduced with
I4F8orI8H4TCR,asassessmentofantiviral inhibitionspecific tothe
endogenous NS31073 viral peptide (1b). (d) Anti-HCV effect on
Lunet-HlaA2-Luc-ubi-neo Con1 replicon cells, and (e) hepatocel-
lular injury caused by TCR-transduced T-cells in quadruple co-
cultures.Meanvaluesand SDare givenand expressedaspercentage
relativelightunits for luciferase(wheremock correspondsto100%),
and international units (I.U.) per litre for aspartate transaminase.
*I n d i c a t e sP value ,0.01 (Student’s t-test) compared with mock.
Dotted line indicates the cut-off value of background biolumin-
escence in empty wells.
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mouse cytokines as reporter protein; unlike primary T-cell
clones, they do not require maintenance through antigen
stimulation or cytokine growth factors, but grow vigor-
ously in simple cell-culture medium without special
supplements. Their activity does not fluctuate in a cyclical
manner, as occurs with some antigen-stimulated T-cell
clones. Freezing and recovery are easy and, moreover, good
viability and activity are usually observed. Some limita-
tions need to be considered here. One is that avidity is
determined in peptide-titration assays and not by the off-
rate of pentamers after binding to the TCR. The second is
that BW-derived hybrids lack CTL function because CD8
expression is suppressed (Rock et al., 1990).
Despite the fact that only one hybridoma (I8H4) here
recognized endogenously processed antigen from human
hepatoma cells that replicate HCV RNA, we note that
functional properties were further improved when I8H4
and I4F8, the latter also a high-avidity TCR, were genetically
transferred and expressed on naı ¨ve non-HCV-specific
human peripheral T-lymphocytes. Both murine TCRs were
highly functional in human CD8 T-cells to give rise to
antigen-specific polyfunctional human CD8
+ T-cells cap-
able of demonstrating at least four effector functions,
including eliminating HCV genotype 1b replicon cells and
causing aspartate aminotransferase (AST) enzyme release.
This is encouraging, as polyfunctional effector T-cells
capable of IL-2 production are associated with effective
control of HCV (Ciuffreda et al., 2008) and represent an
important feature in protective T-cell memory induced by
highly efficacious human vaccines (Ahmed & Akondy,
2011). Because HCV genotype 1 is in general associated
with drug resistance, the notion that our TCRs can cross-
recognize genotype 1a and genotype 1b viral peptides makes
them interesting as immunotherapy candidates.
It is true that we have failed to induce NS31406 T-cells in this
study, because in HLA transgenic mice they are better
induced by peptide vaccination (Brinster et al., 2001).
However, with the current approach we have now generated
new TCRs that target NS5 CTL epitopes that are associated
with control of acute self-limited hepatitis C (A. Pasetto and
others, unpublished data). With the bioluminescent HCV
replicon cells as an indicator for CTL efficiency, it would be
interesting to compare the antiviral potentials in TCR-
modified effector T-cells with various peptide specificities.
In summary, the current study has demonstrated an
efficient way to generate TCR candidates that range in
different functional avidities, with specificity against an
important HCV CTL target. It has implications on the
development of HCV immunotherapy and the under-
standing of T-cell recognition of HCV-infected cells.
METHODS
Animals. Inbred HHD-C57BL/6 (HHD
+H-2D
b2/2b2m
2/2) mice
transgenic for HLA-A2.1, and deficient for both H-2D
b and murine
b2-microglobulin (b2m) (kindly provided by Dr F. Lemonnier,
Institut Pasteur, France) (Pascolo et al., 1997) were maintained at the
Karolinska Institutet, Division of Comparative Medicine (AKM),
Clinical Research Centre, Karolinska University Hospital The
regulations of the Ethical Committee for animal research at the
Karolinska Institutet were followed.
Human PBMCs. PBMCs from healthy blood donors were collected
at the Karolinska University Hospital under informed consent, and
isolated using Ficoll-Hypaque density-gradient centrifugation. Ethical
permission was obtained from the Regional Ethical Review Board
(EPN) of the Karolinska Institutet.
Plasmids and synthetic peptides. The plasmid coNS3/4A-pVAX1,
containing the full-length codon-optimized NS3/4A gene of HCV
genotype 1a, has been described previously (Frelin et al., 2003, 2004).
The HCV NS3 genotype 1a peptides CINGVCWTV (aa 1073–1081)
and KLVALGVNAV (aa 1406–1415) are referred to as NS31073 and
NS31406, respectively (Brinster et al., 2001; Himoudi et al., 2002). Mutant
peptides of NS31073 with indicated alanine (Ala) substitutions were used
as indicated. Other viral peptides tested were: Flu-NA CVNGSCFTV
(aa 231–239); HCV NS31073 genotype 1a CINGVCWTV, genotype 1b
CVNGVCWTV, genotype 2 TISGVLWTV, genotype 3 TIGGVMWTV,
genotype 4 AVNGVMWTV, genotype 5 AINGVMWTV; HCV NS52221
and NS51992 SPDADLIEANL (aa 2221–2231) and VLTDFKTWL
(aa 1992–2000); and HCMV pp65 NLVPMVATV (aa 495–504). All
peptides were synthesized (purity .70%) by ChronTech Pharma AB
and EZBiolab.
Cell lines. BW5147 alpha-beta-cell line (BW TCR
neg cells; kindly
provided by Drs J. Kappler and P. Marrack at the National Jewish
Medical and Research Center) were grown in complete BW medium
[Dulbecco’s modified Eagle’s medium (DMEM) 10% FBS supple-
mented with non-essential amino acids, L-glutamine and gentamicin].
T2, C1R-A2 and C1R-null cells were grown in RPMI 10% FBS with
2m ML-glutamine and 100 mM HEPES. The hepatoblastoma Huh-6
cell line was cultured in DMEM with 10% FBS. T2 is an HLA A2.1
+
cell line, a cloned hybrid between the 721.174 (variant of the LCL 721
B-lymphoblastic cell line) and CEMR.3 (8-azaguanine- and ouabain-
resistant clone of the CEM T-lymphoblastic cell line). C1R-A2 and
C1R-null are Epstein–Barr virus–transformed B-lymphocyte cell lines.
Endogenous peptides bound to HLA-A2 molecules on C1R-A2 cells
were removed by mild acid treatment (pH 3.3) and replaced by HCV
NS3-specific HLA-A2 peptides (Ja ¨ger et al., 1999). All media and
supplements were purchased from Invitrogen.
Generation of HCV NS3-specific T-BW hybridoma clones.
Splenocytes and lymph node cells were isolated from coNS3/4A-
DNA immunized HHD-C57BL/6 mice as described previously (Ahle ´n
et al., 2007). Following 5 days stimulation with HCV NS3 peptides,
CD8
+ T-cells were purified using CD8 MACS MicroBeads (Miltenyi
Biotec) and fused to BW TCR
neg cells. Briefly, the CD8
+ cells were
mixed with BW TCR
neg cells in a 1:5 ratio and PEG1450 (Sigma) was
added; thereafter, the cells were resuspended in minimal essential
medium (MEM) and incubated for 5 min at 37 uC, and cultured for
48 h before selection in HAT (Sigma Aldrich) and HT (HAT without
aminopterin; Gibco, Invitrogen) media. Hybridized cell clones were
maintained in complete BW medium. Positive clones were retested
and regularly subcloned and checked for CD3 expression.
HCV replicon cells. Hepatoma Huh-7-Lunet cells designated Lunet-
HlaA2-neoET, Lunet-blr/neo ET or Lunet-HlaA2 (neo) or Lunet-HLA-
A2-Luc-ubi-neo Con1were generated by rotocol similar to that described
previously (Ahle ´n et al., 2007). The Lunet-HlaA2-neoET has ectopic
HLA-A2 expression and a selectable HCV subgenomic RNA replicon of
genotype 1b, harbouring replication-enhancing mutations in NS3 and
NS4B (Con1-ET). This is the same for Lunet-HLA-A2-Luc-ubi-neo
T-cell receptors against HLA-A2-restricted HCV NS3 antigen
http://vir.sgmjournals.org 255Con1, but it also co-expresses the firefly luciferase gene. The control
replicon cell line Lunet-blr/neo ET was transduced with an empty viral
vector without the HLA-A2 gene. These cells were maintained in
complete DMEM with addition of blasticidin S hydrochloride
(3 mgm l
21) and G418 (1 mg ml
21). Lunet-HlaA2, the other control
cell line (expressing HLA-A2 under blasticidin selection but without the
HCV replicon), was maintained in the same DMEM as above but with
3 mg blasticidin S hydrochloride ml
21 and no G418. For the co-culture
experiments, the Lunet cells were washed and reseeded 1 day before in
antibiotic-free medium. All medium and supplements were purchased
from Invitrogen.
Antibodies and flow cytometry. Antibodies against mouse CD3,
CD8 and human HLA-A2 (BD Biosciences), and R-PE-labelled HLA-
A*0201 Pro5 pentamers refolded with HCV NS31073 or HBV core18–27
(ProImmune) were used. For intracellular multicolour FACS staining,
TCR-transduced PBMCs were incubated overnight with indicated
stimuli. GolgiPlug (BD Biosciences) was added during the final 12 h.
PMA at 50 ng ml
21 and ionomycin at 500 ng ml
21 (Sigma) were
used as a positive control. Cells were then washed and stained with:
Pacific Blue–anti-human CD3 (Biolegend), allophycocyanin–Cy7–
anti-human CD8a (Biolegend), FITC-labelled anti-mouse Vb 8.3 (BD
Biosciences), anti-mouse Vb8.1-8.2 (BD Biosciences), anti-mouse
Vb6 (BD Biosciences), anti-mouse Vb4 (BD Biosciences), allo-
phycocyanin–anti-human IL-2 (Biolegend), PE–anti-human IFN-c
(Biolegend) and PE–Cy7–anti-human TNF (BD Biosciences). A BD
Cytofix/Cytoperm fixation/permeabilization kit was used. Cells were
analysed using a BD LSRFortessa flow cytometer and FlowJo 9.2 (Tree
Star) software.
Measurement of cytokine release. Target cells (2610
5) were
cultured for 24 or 48 h with equal numbers or the indicated number
of each BW-T cell hybrid clone in duplicates with or without different
viral peptides. Concentrations of mouse IL-2 and IFN-c in the
supernatant were measured using mouse IL-2 or IFN-c ELISA
(Mabtech) and calculated against standard curves generated with a
cytokine standard.
TCR gene typing and sequencing, and retroviral TCR con-
structs. Total RNA was reverse-transcribed to cDNA using Super-
Scipt III RT enzyme (Invitrogen). TCR variable alpha (VA) and
variable beta (VB) chain typing was done by PCR with Platinum Taq
polymerase (Invitrogen) and primer sets covering the entire murine
TCR VA and VB repertoire. PCR products were cloned (pCR-4
TOPO system, Invitrogen) and the plasmids were sequenced by
Eurofins MWG (Ebersberg). Sequences were analysed and classified
according to the nomenclature given in the Immunogenetics database
(European Bioinformatics Institute, Cambridge, UK). Full-length
TCR genes were amplified and, after sequence confirmation, synthetic
genes linked with the autoprotease 2A sequence were made
(GeneArt, LifeTechnology) and assembled into pMP-71-G-Pre retro-
viral plasmid (kindly provided by Wolfgang Uckert, Max-Delbru ¨ck-
Center for Molecular Medicine). Phoenix amphotropic packaging line
(Nolan’s lab, Standford University) was used to package the
expression plasmids for expression in primary human T-cells.
Calcium phosphate transfection was done with 20 mg of each vector
(pMP71-NS3-H4, pMP71-NS3-F8, pMP71-NS5-19, pMP71-NS5-69
and pMP71-EGFP) and 12.5 ml of 50 mM chloroquine.
Retrovirus transduction. Human PBMCs were stimulated with 600
or 300 U IL-2 ml
21 (R&D System or Prepotech) and 50 ng anti-
CD3 ml
21 (OKT-3 eBioscience). Lymphocytes were harvested
and transduced by spinoculation on retronectin-coated wells with
polybrene (Millipore). Spinoculation was repeated the next day and
TCR surface expression was analysed by FACS 72 h after the first
spinoculation.
Bioluminescence cell imaging and transaminase measure-
ment. Either 50000 or 100000 Lunet-HlaA2-Luc-ubi-neo Con1
cells were co-cultured with transduced or mock-transduced T-cells
in a ratio of 2:1. Following 20 h co-incubation the medium was
replaced with luciferin solution prior to imaging with a charge-
coupled device camera. Signals from bioluminescent Lunet-HlaA2-
Luc-ubi-neo Con1 cells were analysed with the Living Image
Software version 4.2 and IVIS Spectrum instrument (Caliper Life
Sciences). The AST level in supernatants was quantified by a
validated AST assay at the Clinical Chemistry Laboratory at the
Karolinska University Hospital.
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